
A research team led by Georgia State University has developed a novel collagen-targeted magnetic resonance imaging (MRI) contrast agent that detects invasive lung cancer and metastatic disease with greater sensitivity than conventional imaging approaches.
“Lung cancer is often diagnosed only after it has spread, when treatment options become more limited,” said senior author Jenny Yang, PhD, Georgia State University Regents’ professor emerita of biochemistry and biophysical chemistry. “Our technology can detect tiny tumors and hidden metastases without exposing patients to radiation. It also helps reveal how aggressive a cancer may be and how likely it is to spread, potentially reducing the need for invasive biopsies.”
Yang and team explain in Science Advances that current imaging methods cannot reliably detect tumors smaller than one centimeter. Yet the their precision MRI method can identify tumors and metastases as small as one millimeter.
To achieve such sensitivity, Yang and colleagues created hProCA32.Collagen, a protein MRI contrast agent targeting collagen I that uses human parvalbumin as a scaffold protein and contains two gadolinium (Gd)3+ binding sites. The team chose collagen as their target because changes in expression of the protein have been observed in patients with lung cancer, correlating with TNM stage, tumor type, and lymph node and distant metastases.
Studying the performance of hProCA32.Collagen in preclinical models of lung adenocarcinoma with LKB1/STK11 inactivation, the researchers found that hProCA32.Collagen had 10-fold higher relaxivity than currently approved Gd3+ contrast agents, such as Gadovist. They note that relaxivity is a measure of how strongly an MRI contrast agent affects the MRI signal, with higher numbers linked to greater contrast between different tissue types, which translates into greater imaging sensitivity.
In addition, hProCA32.Collagen enabled the detection of multiple lung nodules with contrast-to-noise (CNR) enhancements that were 3- to 15-fold higher than with computed tomography (CT) imaging and 1.8- to 3-fold higher than with Gadovist. Indeed, CT imaging missed 28% of small (0.6–1.9 mm) lung nodules that were successfully captured by hProCA32.Collagen.
When looking at metastases, Yang and co-investigators found that the CNR was 2- to 4-fold higher with hProCA32.Collagen than with Gadovist for lung tumors for adrenal metastases, while CT failed to detect any distant metastases in the adrenal glands.
Moreover, area under the curve analyses suggested that hProCA32.Collagen provided approximately 8-fold greater sensitivity for detecting lung and adrenal metastases than Gadovist.
Yang told Inside Precision Medicine that hProCA32.Collagen could have “broad medical impact for lung cancer patients,” including improved safety for children and pregnant women that cannot use CT for detection, earlier detection, image guided treatment, and informed follow-up with a reduced need for biopsy.
She said that her team has already developed manufacturing processes suitable for scaled up production once toxicity documentation and clinical trials for safety and efficacy are complete.
Yang also noted that hProCA32.Collagen shows potential beyond lung adenocarcinoma. “It can be applied for many types of cancer patients,” she said. “We have shown efficacy for liver, pancreatic, breast, and colon cancer plus metastasis to liver in more than 10 animal models.”





